Predictors of sustained response to alpha interferon therapy in chronic hepatitis C

Journal of Hepatology

Volumn 29, Issue 2, 1998, Pages 214-223

  Martinot Peignoux, Michèle ^a   Boyer, Nathalie ^a   Pouteau, Michèle ^a   Castelnau, Corinne ^a   Giuily, Nathalie ^a   Duchatelle, Véronique ^b   Aupérin, Anne ^a   Degott, Claude ^b   Benhamou, Jean Pierre ^a   Erlinger, Serge ^a   Marcellin, Patrick ^a,b  

^a INSERM   (France)

^b BEAUJON HOSPITAL   (France)

Author keywords

Chronic hepatitis C; HCV genttype; IFN therapy; Predictive factors; Serum HCV RNA; Sustained response

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHAN1 INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS TYPING;

EID: 0032146432     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80006-8     Document Type: Article

References (34)

1. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med. 315:1986;1575-1578.
2. Di Bisceglie A, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alpha therapy for chornic hepatitis C. A randomized double-blind placebo-controlled trial. N Engl J Med. 321:1989;1506-1510.
3. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, et al. Treatment for chro6nic hepatitis C with recombinant interferon alpha. A multicenter randomized controlled trial. N Engl J Med. 321:1989;1501-1516.
4. Marcellin P, Boyer N, Giostra E, Degott C, Couroucé AM, Degos F, et al. Recombinant human alpha interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology. 13:1991;393-397.
5. Cause X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with non-A, non-B hepatitis. Gastroenterology. 101:1991;497-502.
6. Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, et al. Long term follow-up of patients with chronic hepatitis C treated with different doses of interferon alpha-2b. Hepatology. 226:1997;347-356.
7. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med. 226:1997;347-356.
8. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon α therapy. Ann Intern Med. 127:1997;875-881.
9. Jouet P, Roudot-Thoraval F, Dhumaux D, Metreau JM. Comparative efficacy of interferon alpha in cirrhotic and non-cirrhotic patients with non-A, non-B hepatitis. Le groupe français pour l'étude du traitement des hépatites chroniques NANB/C. Gastroenterology. 106:1994;686-690.
10. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trépo C, et al. A comparison of three interferon alfa-2b regimens for the long term treatment of chronic non-A, non-B hepatitis. N Engl J Med. 332:1995;1457-1462.
11. Marcellin P, Pouteau M, Martinot-Peignoux M, Degos F, Duchatelle V, Boyer N, et al. Lack of benefit of escalating dosage of interferon alpha in patients with chronic hepatitis C. Gastroenterology. 109:1995;156-165.
12. Chemello L, Bonetti P, Cavalleto L, Talato F, Donadon V, Casarin P, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology. 22:1995;700-706.
13. Lindsay KL, Davis GL, Schiff E, Bodenheimer HC, Balart LA, Dienstag JL, et al. Response to higher doses of interferon alfa 2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatology. 24:1996;1034-1040.
14. Serfaty L, Giral P, Loria A, Andréani T, Legendre C, Poupon R. Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol. 21:1994;12-7.
15. Pagliaro L, Craxi A, Cammaà C, Tiné F, Di Marco V, Lo Jacono O, Almasio P. Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology. 19:1994;820-828.
16. Lau JYN, Davis GL, Kniffen J, Quian KP, Urdea MS, Chan CS, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet. 341:1993;1501-1504.
17. Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Bréchot C. Hepatitis C virus type 1b (II)_infection in France and Italy. Ann Intern Med. 122:1995;161-168.
18. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquen M, et al. Pretreatment serum HCV RNA levels and HCV genotype are the main and independent prognostic factors of sustained response to alpha interferon therapy in chronic hepatitis C. Hepatology. 22:1995;1050-1056.
19. Pawlotsky JM, Roudot-Thoraval, Bastie A, Darthuy F, Rémiré J, Métreau JM, et al. Factors affecting treatment response to interferon alpha in chronic hepatitis C. J Infect Dis. 174:1996;1-7.
20. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tomonaga T, Persing DH. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med. 125:1996;634-639.
21. Magrin S, Craxi A, Fabiano C, Marino L, Fiorentino G, Lo Iacono O, et al. HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (Southern Italy). J Hepatol. 25:1996;583-590.
22. Lau JYN, Simmonds P, Urdea M. Implication of variations of "conserved" regions of hepatitis C virus genome. Lancet. 346:1995;425-426.
23. Marcellin P, Pouteau M, Boyer N, Degos F, Castelnau C, Degott C, et al. Usefulness of prolonging interferon therapy according to the initial response in patients with chronic hepatitis C without cirrhosis [abstract]. Hepatology. 20:1994;154.
24. Benhamou JP, Hopf U, Rizzetto M, Sanchez-Tapias JM, Braconnier JH, Bulher H, et al. Long-term lymphoblastoid interferon enhances sustained response and improves histological activity up to 12 months post-treatment [abstract]. Hepatology. 22:1995;37.
25. Bacon BR, Farell G, Benhamou JP, Hopft U, Barcena R, Feinman V, et al. Lymphoblastoid interferon improves longterm response to a six month course of treatment when compared with recombinant interferon alfa 2b: results of an international trial [abstract]. Hepatology. 22:1995;37.
26. Knodell RG, Ishak KG, Black WC. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1:1981;431-435.
27. Davis G, Lau JY, Urdea MS, Neuwald PD, Wilbert JC, Lindsay K, et al. Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification method: definition of the optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology. 19:1994;1337-1341.
28. Young KK, Resnick RM, Myers TW. Detection of hepatitis C virus RNA by combined reverse transcription-polymerase chain reaction assay. J Clin Microbiol. 31:1993;882-886.
29. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol. 74:1993;1093-1102.
30. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology. 19:1994;1321-1324.
31. Conjeevaram HS, Everhart JE, Hoofnagle JH. Predictors of a sustained beneficial response to interferon alfa therapy in chronic hepatitis C. Hepatology. 22:1995;1326-1329.
32. Tiné F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomized clinical trials. J Hepatol. 13:1991;192-199.
33. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Effects of dose and duration. Hepatology. 24:1996;778-789.
34. Davis G, Lau J. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology. 20:1997;123-127. (Suppl).